Posted by Michael Wonder on 28 Mar 2024
89bio receives EMA PRIME status for pegozafermin in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis and compensated cirrhosis
27 March 2024 - PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin.
89bio today announced that the EMA has granted Priority Medicines (PRIME) status to pegozafermin in patients with MASH.
